Oral Session 2-8C DLBCL: Treatment

[OS2-8C-3] A retrospective analysis of tolerability and safety of DA-EPOCH ± Rituximab for aggressive lymphoma

Shinichiro Matsuda¹, Youko Suehiro², Naoto Tomita³, Koji Izutsu⁴, Noriko Fukuhara⁵, Yoshitaka Imaizumi⁶, Kazuyuki Shimada⁷, Tomonori Nakazato⁸, Isao Yoshida⁹, Tsutomu Takahashi¹, Ritsuro Suzuki¹, Motoko Yamaguchi¹⁰, Junji Suzumiya¹ (1.Oncology/Hematology, Shimane University Hospital, Shimane, Japan, 2.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 3.St. Marianna University School of Medicine, Kanagawa, Japan, 4.Hematology, Toranomon Hospital, Tokyo, Japan, 5.Hematology, Tohoku University Hospital, Miyagi, Japan, 6.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 7.Hematology, Nagoya University Hospital, Aichi, Japan, 8.Hematology, Yokohama Municipal Citizens Hospital, Kanagawa, Japan, 9.Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan, 10.Hematology and Oncology, Mie University Hospital, Mie, Japan)